Top Page
Wellnex Life Ltd
(Sydney:WNX)
Wellnex Life Ltd (WNX) vs. iShares MSCI Australia ETF (EWA)
Wellnex Life Ltd Business Overview & Revenue Model
Wellnex Life Ltd Financial Statement Overview
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.24M | 16.93M | 27.89M | 18.61M | 1.20M | 934.00K |
| Gross Profit | 6.19M | 4.11M | 4.75M | 4.50M | -165.00K | 447.00K |
| EBITDA | -5.83M | -10.57M | -6.82M | -6.35M | -18.41M | -9.45M |
| Net Income | -11.51M | -13.74M | -13.85M | -7.45M | -24.69M | -46.27M |
Balance Sheet | ||||||
| Total Assets | 31.92M | 30.92M | 15.04M | 19.61M | 10.42M | 19.23M |
| Cash, Cash Equivalents and Short-Term Investments | 280.00K | 903.00K | 322.00K | 3.18M | 7.78M | 1.14M |
| Total Debt | 12.37M | 10.67M | 6.95M | 7.86M | 9.31M | 5.80M |
| Total Liabilities | 28.87M | 24.86M | 14.45M | 15.25M | 10.67M | 16.41M |
| Stockholders Equity | 3.04M | 6.06M | 594.00K | 4.36M | -249.00K | 18.63M |
Cash Flow | ||||||
| Free Cash Flow | -893.50K | -6.82M | -6.19M | -8.65M | -5.17M | -31.34M |
| Operating Cash Flow | -3.89M | -6.82M | -6.19M | -8.61M | -4.38M | -7.57M |
| Investing Cash Flow | -290.00K | -13.42M | -2.20M | -3.65M | 9.45M | -16.92M |
| Financing Cash Flow | 5.70M | 20.82M | 5.53M | 7.66M | 1.65M | 7.28M |
Wellnex Life Ltd Technical Analysis
Wellnex Life Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | AU$18.76M | ― | ― | -5.86% | 98.26% | ||
49 Neutral | AU$2.49B | 4.37 | -64.25% | 2.83% | 36.51% | 13.14% | |
44 Neutral | AU$23.47M | ― | -47.74% | ― | 43.14% | 51.35% | |
39 Underperform | €17.96M | ― | -240.42% | ― | 14.41% | 76.26% | |
34 Underperform | AU$8.62M | ― | -105.17% | ― | -3.82% | 51.47% | |
31 Underperform | AU$4.76M | ― | ― | -16.29% | 58.77% |
Wellnex Life Ltd Corporate Events
Wellnex Life Limited has divested the assets of The Iron Company brand to CW Retail Holdings Pty Ltd, part of the Chemist Warehouse group, as part of its strategy to focus on key brands like Pain Away, Wakey Wakey, and Nighty Night. This move follows an internal review post its AIM listing and aims to enhance trade activity within the Chemist Warehouse group, aligning with Wellnex’s renewed strategic focus.
Wellnex Life Limited (ASX: WNX) has announced the reinstatement of its securities to trading on the ASX following a suspension. This comes after the company addressed queries from the ASX regarding a previous announcement made on May 26, 2025. The lifting of the suspension is expected to positively impact the company’s market operations and reassure stakeholders about its compliance and transparency.
Wellnex Life Limited has retracted its previous announcement from May 26, 2025, due to concerns over the accuracy and reliability of prospective financial information in a research report by SP Angel, its UK broker. The company clarified that while it provided financial data to SP Angel, it does not endorse the report’s prospective financial information, leading to the retraction to maintain compliance with regulatory standards.
Wellnex Life Ltd has retracted financial forecasts previously shared in a research report produced by SP Angel, one of its UK-based brokers. The company had initially provided SP Angel with both public and internal financial targets for FY25 and FY26, which were used to generate independent forecasts. However, the company has since withdrawn these projections, which were based on assumptions of continued revenue growth, increased product distribution, and realization of sales targets.
The securities of Wellnex Life Ltd have been suspended from quotation by the ASX to prevent a disorderly or uninformed market. This suspension is pending the company’s response to queries from the ASX regarding a recent announcement titled ‘Letter to Shareholders’, which may impact the company’s market positioning and stakeholder relations.
Wellnex Life Limited has announced significant growth and strategic advancements, including a 46% increase in revenue and a 55% rise in gross profit for the period of January to April 2025 compared to the previous year. The company has also eliminated $13 million in liabilities, reducing financial risks and interest costs, and is focusing on profitable, sustainable growth by streamlining its offerings and concentrating on high-potential brands. This marks a pivotal point for Wellnex, as it aims to maximize shareholder value and achieve sustainable cash flow.
Wellnex Life Limited announced the cessation of George Tambassis as a director, effective from May 6, 2025. The notice indicates that Tambassis held no relevant interests in securities as a registered holder or through other entities, suggesting minimal immediate impact on the company’s operations or market positioning.
Wellnex Life Limited has announced changes to its board and management following a successful dual listing on the AIM Market of the London Stock Exchange. Non-Executive Chairman George Tambassis has resigned due to external commitments, and Andrew Vidler, an independent Non-Executive Director, will serve as interim Chairman. The company has also appointed Zack Bozinovski as joint CEO to focus on business growth and shareholder value. These changes aim to ensure a seamless transition and continued expansion in the healthcare market.
Wellnex Life Limited has appointed Powermed Plus as its UK distributor to expand its innovative brands into the UK market. This strategic move follows Wellnex Life’s recent admission to the AIM market, which is expected to boost brand awareness and sales in the UK. The collaboration with Powermed Plus, a seasoned healthcare services provider, is set to commence in Q3 2025, with sales planned for 2026, marking a significant growth phase for Wellnex Life.
Wellnex Life Limited reported a significant increase in cash receipts and sales for Q3 FY25, with cash receipts rising by 69% and sales increasing by 35% compared to the previous quarter. The company achieved a positive net cash flow from operations and noted substantial growth in its high-margin brands and IP licensing. The completion of its admission to the AIM market of the London Stock Exchange is a pivotal development, expected to drive international expansion and result in annual cost savings of $1.4 million. This strategic move, along with the extinguishment of convertible notes and the acquisition of Pain Away, positions Wellnex Life for enhanced financial growth and operational scale.